Xofluza® (baloxavir marboxil) – Expanded indication
March 1, 2024 - The FDA approved Genentech’s Xofluza (baloxavir marboxil), for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications.